About enasidenib
Isocitrate dehydrogenase-2 inhibitor
Used for
- Treats adults with relapsed or refractory acute myeloid leukemia with a susceptible IDH2 mutation.
Usual adult dose
100 mg by mouth once daily, continued until disease progression or unacceptable side effects.
Common side effects
- Nausea, vomiting, diarrhea, or decreased appetite
- High bilirubin levels
- Fatigue or muscle pain
- Differentiation syndrome, which can be life-threatening
Important warnings
- Differentiation syndrome may cause fever, breathing problems, swelling, or kidney problems; it requires urgent treatment.
- Can cause fetal harm; pregnancy testing and effective contraception are recommended during treatment and for two months afterward.
- Monitor blood counts, liver function, and bilirubin during treatment.
- Tumor lysis syndrome can occur, especially early in treatment.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment and for two months after the last dose.
Breastfeeding
Do not breastfeed during treatment and for two months after the last dose.
Interactions
- Strong CYP3A inducers can lower enasidenib levels.
- Enasidenib can reduce levels of some CYP3A substrates, including hormonal contraceptives.
- May alter levels of certain transporter-substrate medicines, including some statins.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.